358 related articles for article (PubMed ID: 28146003)
1. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 May; 23(5):E26-E37. PubMed ID: 30052985
[TBL] [Abstract][Full Text] [Related]
3. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
4. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
5. Budesonide for induction of remission in Crohn's disease.
Rezaie A; Kuenzig ME; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH; Kaplan GG; Seow CH
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD000296. PubMed ID: 26039678
[TBL] [Abstract][Full Text] [Related]
6. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
Moja L; Danese S; Fiorino G; Del Giovane C; Bonovas S
Aliment Pharmacol Ther; 2015 Jun; 41(11):1055-65. PubMed ID: 25864873
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Townsend CM; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
[TBL] [Abstract][Full Text] [Related]
8. Budesonide for induction of remission in Crohn's disease.
Seow CH; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH
Cochrane Database Syst Rev; 2008 Jul; (3):CD000296. PubMed ID: 18646064
[TBL] [Abstract][Full Text] [Related]
9. Budesonide for maintenance of remission in Crohn's disease.
Benchimol EI; Seow CH; Otley AR; Steinhart AH
Cochrane Database Syst Rev; 2009 Jan; (1):CD002913. PubMed ID: 19160212
[TBL] [Abstract][Full Text] [Related]
10. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis.
Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV
Gastroenterology; 2015 Jan; 148(1):64-76.e2; quiz e14. PubMed ID: 25263803
[TBL] [Abstract][Full Text] [Related]
12. Medical management of Crohn's disease.
Cottone M; Renna S; Orlando A; Mocciaro F
Expert Opin Pharmacother; 2011 Nov; 12(16):2505-25. PubMed ID: 21988215
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
[TBL] [Abstract][Full Text] [Related]
16. Oral budesonide for induction of remission in ulcerative colitis.
Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
[TBL] [Abstract][Full Text] [Related]
18. [5-aminosalicylic acid for induction of remission or clinical response in Crohn's disease--a survey of a Cochrane review].
Bjerrum JT; Munck LK; Nielsen OH
Ugeskr Laeger; 2011 Aug; 173(35):2110-3. PubMed ID: 21884660
[TBL] [Abstract][Full Text] [Related]
19. Steroid use in Crohn's disease.
Vavricka SR; Schoepfer AM; Scharl M; Rogler G
Drugs; 2014 Mar; 74(3):313-24. PubMed ID: 24532122
[TBL] [Abstract][Full Text] [Related]
20. Update on the management of Crohn's disease.
Buchner AM; Blonski W; Lichtenstein GR
Curr Gastroenterol Rep; 2011 Oct; 13(5):465-74. PubMed ID: 21792543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
